Scenario drafting to anticipate future developments in technology assessment by Retel, V.P. et al.
Retèl et al. BMC Research Notes 2012, 5:442
http://www.biomedcentral.com/1756-0500/5/442RESEARCH ARTICLE Open AccessScenario drafting to anticipate future
developments in technology assessment
Valesca P Retèl1, Manuela A Joore2,3, Sabine C Linn4, Emiel JT Rutgers5 and Wim H van Harten1,6*Abstract
Background: Health Technology Assessment (HTA) information, and in particular cost-effectiveness data is needed
to guide decisions, preferably already in early stages of technological development. However, at that moment there
is usually a high degree of uncertainty, because evidence is limited and different development paths are still
possible. We developed a multi-parameter framework to assess dynamic aspects of a technology -still in
development-, by means of scenario drafting to determine the effects, costs and cost-effectiveness of possible
future diffusion patterns. Secondly, we explored the value of this method on the case of the clinical
implementation of the 70-gene signature for breast cancer, a gene expression profile for selecting patients who will
benefit most from chemotherapy.
Methods: To incorporate process-uncertainty, ten possible scenarios regarding the introduction of the 70-gene
signature were drafted with European experts. Out of 5 most likely scenarios, 3 drivers of diffusion (non-compliance,
technical failure, and uptake) were quantitatively integrated in a decision-analytical model. For these scenarios, the
cost-effectiveness of the 70-gene signature expressed in Incremental Cost-Effectiveness Ratios (ICERs) was compared
to clinical guidelines, calculated from the past (2005) until the future (2020).
Results: In 2005 the ICER was €1,9 million/quality-adjusted-life-year (QALY), meaning that the 70-gene signature
was not yet cost-effective compared to the current clinical guideline. The ICER for the 70-gene signature improved
over time with a range of €1,9 million to €26,145 in 2010 and €1,9 million to €11,123/QALY in 2020 depending on
the separate scenario used. From 2010, the 70-gene signature should be cost-effective, based on the combined
scenario. The uptake-scenario had strongest influence on the cost-effectiveness.
Conclusions: When optimal diffusion of a technology is sought, incorporating process-uncertainty by means of
scenario drafting into a decision model may reveal unanticipated developments and can demonstrate a range of
possible cost-effectiveness outcomes. The effect of scenarios give additional information on the speed with cost
effectiveness might be reached and thus provide a more realistic picture for policy makers, opinion leaders and
manufacturers.
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Especially in early stages of promising new technologies,
Health Technology Assessment (HTA) information
should be used to anticipate possible developments. Per-
forming a HTA requires sufficient patient numbers and,
as a consequence, broad clinical implementation of new
technologies may be premature in the absence of firm
prospective data on the actual benefits [1]. However, if
we wait to perform a HTA, it might very well be that
worthwhile technology is withheld from the public [2].
This paradox has become known as Buxton’s law: “It is
always too early, until suddenly, it is too late. . .” [3]. We
feel that there is a need to integrate methods in TA for
dealing with the various possible developments in early
stages of technology development, both to support infor-
mation for policy makers, opinion leaders and manufac-
turers, and to anticipate developments encountered
during the early introduction in clinical practice. Com-
bining structured scenario drafting and decision model-
ling could be helpful to integrate these dynamics when
calculating expected effects and costs.
The question is whether HTA –in the broad sense of
the term- can be conducted in advance of widespread
adoption of a technology? This question has also been
featured by a rich body of publications in the recent years
[4-7], however, none of these articles focused on incorp-
oration of qualitative scenarios from the perspective of
various stakeholders into a cost-effectiveness model.
An example of a promising technique in its early
stages of development is the 70-gene prognosis signature
(MammaPrintTM) for breast cancer patients [8]. Using
the 70-gene signature, the selection of patients that will
benefit most from chemotherapy could be more accurate
compared to currently used clinical guidelines, and
thereby reducing over-treatment. The promising results
of three retrospective validation studies [9-11] led to the
performance of a prospective feasibility study (RASTER:
MicroarRAy PrognoSTics in Breast CancER) from 2004
until 2006 [12], followed by a prospective, randomized
clinical trial (MINDACT: Microarray In Node-negative
Disease may Avoid ChemoTherapy), from 2007 until
2011 [13].
It would take at least 8–10 years to bring the signature
into routine clinical practice via the usual path of pro-
spective trials [14]. It was therefore decided that the
controlled introduction of this technology, starting in
2004, should be supported by an early and dynamic form
of HTA; Constructive Technology Assessment (CTA).
CTA is based on the idea that during the course of
technology development, choices are constantly being
made about the form, the function, and the use of that
technology [15,16], and attempts to influence the devel-
opment and diffusion of a new technology in a beneficial
way [17].For the introduction of the 70-gene signature, the
CTA-part focused on quality aspects that were most
likely to change during the introduction, such as: effi-
ciency, logistics, ethical/legal aspects, patient centered-
ness and cost-effectiveness [18-20]. From the cost-
effectiveness analysis was learned that the 70-gene had
the highest probability of being cost-effective compared
to the currently used clinical guidelines St. Gallen guide-
lines [21] and the Adjuvant! Online software [22] for a
willingness to pay more than €4,614/QALY [20].
Simultaneous with the early introduction, scenarios
were drafted to monitor and anticipate these changing
aspects, in other words: the dynamics of the 70-gene sig-
nature diffusion. The scenarios were written in two
steps; firstly, two overall scenarios were developed and
secondly, a scenario workshop with more detailed sce-
narios was organized.
The technology-related developments and the diffu-
sion pathway of the 70-gene signature are likely to have
impact on the cost, effects and cost-effectiveness in the
future. In cost-effectiveness analyses (CEAs), it is com-
mon to use different quantitative scenarios in sensitivity
analyses to reflect the uncertainty of input-parameters
[23]. There are only a few examples in the literature
where more comprehensive, qualitative scenarios were
processed into a CEA [24,25].
Our research objectives were: first, to develop a multi-
parameter framework to assess dynamic aspects to deter-
mine the effects, costs and cost-effectiveness of possible
future diffusion patterns of technologies at an early stage
of development. Second, to illustrate this method for the
70-gene signature versus the current Adjuvant! Online
(AO) treatment strategy for breast cancer patients.
Methods
The following steps in the multi-parameter framework
can be distinguished: (I) determination of the phase of
diffusion; (II) scenario construction; (III) grouping of
scenarios; (IV) integration of the factors as parameters
in the decision model; (V) input model parameters; (VI)
model analysis.
Determination of the phase of diffusion
To position the scenarios in a timeline, we used the ‘dif-
fusion theory’ of Rogers [26], where several phases re-
flect the diffusion path of the technology related to the
numbers of adopters (Figure 1). “Diffusion is the process
by which an innovation is communicated through cer-
tain channels over time among the members of a social
system” [26]. The possible developments as described in
a scenario can have influence on the degree and speed
of diffusion of the technology in clinical practice.
In the case of the 70-gene signature, the diffusion
pathway is described following the curve as in Figure 1:
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Figure 1 Rogers’ adoption curve with possible diffusion patterns.
Retèl et al. BMC Research Notes 2012, 5:442 Page 3 of 12
http://www.biomedcentral.com/1756-0500/5/442innovation phase (2003–2005), the prognosis signature
technique was developed and the first organisations
(innovators) adopted the technology in their daily prac-
tice. The early adoption phase (2005–2007) describes
the implementation in 10–15 hospitals: the logistics
were established and physicians increasingly based their
adjuvant treatment decision on the signature result. The
early majority phase (2007–2012 and beyond) describes
the implementation in a gradually increasingly number
of hospitals participating in the prospective randomised
controlled MINDACT-trial [27].
Scenario construction
The method we used to construct the scenarios was
based on the Shell (Royal Dutch Oil multinational) ap-
proach, using a most likely course of development with
‘There Is No Alternative’ (TINA) elements and the dy-
namic nature introduced by ‘what if ’-deviations [28]. The
Shell method consists of background research, drafting
one or two scenarios, structured feedback by experts and
revision of these drafts [29,30]. In fact, the scenario plan-
ning concerns planning based on the systematic examin-
ation of the future by picturing plausible and consistent
images thereof. A specific element in this method is theintroduction of “what if” deviations; especially in early
stages the degree of uncertainty may render it helpful to
consider alternatives. The Delphi method, in turn,
attempts to develop systematically expert opinion con-
sensus concerning specific aspects of future develop-
ments and events. It is a judgmental decision and/or
forecasting procedure in form of an anonymous, written,
multi-stage survey process, where feedback of group
opinion is provided after each round. Generally speaking,
the output of the different phases of the Delphi method
can be used as input for the scenario method. More
background details will be found at the Shell website
[28] and a former publication concerning this subject
[15].
We used a semi-structured questionnaire to present
ten scenario related options as “What if. . .” statements
to genomic experts and breast cancer specialists; mem-
bers of the TRANS- breast international group
(TRANSBIG). These are the health care professionals
that are going to use or work with the 70-gene array in
the (future) daily practice. The responses of the ques-
tionnaires were used as feedback for the ultimate scenar-
ios presented at a workshop with a formal decision
procedure, which was attended by 80 participants
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and radiotherapists). These experts were asked to vote
on the 10 scenario options; they had to indicate, whether
each alternative was “likely” or “unlikely” to happen
within 10 years. The resulting scenarios are described in
Table 1.
Grouping of scenarios
For the scenarios to be incorporated in the cost-
effectiveness modelling we used a structured decision
process (Figure 2). From the ten “workshop” scenarios,
the five most likely were selected by ranking the likeli-
ness of the scenarios. The most crucial accelerating or
decelerating aspects (drivers of the diffusion) wereTable 1 Scenario results and likelihoods derived from the wo
Workshop Scenario
1 Hesitant adopters
(100% likely)
2 User-friendliness
(90% likely)
3 Progressive techniques
(90% likely)
4 Progressive uptake
(90% likely)
5 Financial access
(75% likely)
6 Other paraffin/test
(60% likely)
7 Competitive test
(60% likely)
8 Era after: CTC?
(40% likely)
9 Provision on free
market (18% likely)
10 Regulation/legislation
barrier (5% likely)
CTC: circulating tumour cells, ER/PgR: oestrogen and progesterone receptors.identified which resulted in three main factors: technical
failure, non-compliance with discordant test results, and
uptake. Technical failure was based on the “user-
friendliness” and “RNA preservation” workshop-scenario.
Non-compliance was based on the “hesitant adopters”
scenario. We noticed that from the moment the first
papers appeared quite some opinion leaders were rather
sceptical to the value of the test, which related mostly
to methodological issues and possibly to the lack of
knowledge on this new genomic and medical technical
domain. As this seemed to defer the stages of diffusion
after innovation and early adoption (cf Rogers) and
strong criticisms were voiced, we labelled these “hesi-
tant adopters”. Uptake was based on the “financialrkshop with experts
Description
Professionals, who are not using the 70-gene signature
until the results of the MINDACT are released, will delay the
diffusion (spreading of the signature) process. This will be
expressed in the proportion of non-compliance towards the
signature result.
There is a mix of new functions possible on the (read-out)
microarray; such as ER/PgR/Her2 status, singles genes,
with new possibilities for e.g. targeted therapies.
Furthermore, by using needle biopsies the application
becomes more user-friendly. This will be expressed in a
decrease of failures of the signature.
There is positive proof for the value of RNA-preservation
instead of formalin-based tissue for future research, which
causes an increased use of the 70-gene signature. This will
be expressed in a decrease of failures of the signature.
The 70-gene signature has developed further and can be
used safely for all node negative and 1–3 positive patients.
The uptake is 100% in your county and is embedded in the
national guidelines. This will be expressed in an increasing
number of patients receiving signature.
The insurance companies in the Netherlands don’t
reimburse the use of the 70-gene signature yet (2008). If the
insurers were to reimburse the 70-gene signature, the rate of
reimbursement agreements would be rather more
progressive throughout Europe. This will be expressed in a
–slightly slow- increase of patients receiving the signature.
Another PRC-based, user-friendly test appears on the
market, and the market share of the 70-gene signature
decreases.
The Oncotype DX ‘wins’ the competition; the market share
of the 70-gene signature decreases.
A totally new (nano) technology has been developed (using
fresh frozen tumour samples) which has more value than
the 70-gene signature and - due to this test - the market
share of the 70-gene signature decreases.
Besides being used in the MINDACT trial, 70-gene
signature is also available on the free market, to prevent
unethical situations due to patient selection.
There is a probability of legal regulation by way of FDA
clearance. Because the 70-gene signature has FDA and
IVDMIA (In Vitro Diagnostic Multivariate Index Assay)
approval, the market share of the Oncotype DX decreases.
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send to
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10 scenarios adjusted
EU Workshop organized to
discuss 10 adjusted scenarios
80 international experts
Voting during workshop:
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Realisation scenarios withIn
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Resulting in separate and 
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Figure 2 Scenario method and structured decision, based on the Shell method [28].
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sive uptake” scenario (rapid increase in uptake). The
three drivers of diffusion were incorporated as para-
meters in the decision model, see Table 2.
Integration of the driving factors as parameters in the
decision model
A Markov decision model was previously developed to
assess the effects (quality-adjusted life years; QALYs),
costs and cost-effectiveness of the 70-gene signature
compared to clinical-pathological guidelines (such asAdjuvant! Online [22]) for patients aged 50 years with
early, operable, node-negative, oestrogen receptor (ER)
positive breast cancer. In each strategy, based on the
sensitivity and specificity of the prognostic test calcu-
lated from a pooled analysis consisting of 3 previously
reported validation studies, patients were classified as
having a true low, true high, false low, or false high risk
of developing metastasis. It was assumed that both the
prognostic test result and the treatment guidelines
would be followed in all cases. We simulated in the
model that all patients received endocrine treatment,
Table 2 Input parameters
Workshop scenario Barrier or
facilitator?
Drivers of diffusion
(Parameter in
decision model)
Mean parameter
value in decision
model
Source
1 Hesitant adopters Barrier Non-compliance 2005 0.35 12
2010 0.26 Scenario workshop
2020 0.08 Scenario workshop
2 & 3 User friendliness &
Progressive techniques
Barrier Technical failure 2005 0.27 12
2010 0.20 Scenario workshop
2020 0.08 Scenario workshop
4 & 5 Progressive uptake &
Financial access
Facilitator Uptake 2005 0.03 12
2010 0.50 Scenario workshop
2020 0.92 Scenario workshop
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chemotherapy. The model was constructed with four
mutually exclusive health states: disease free survival, re-
lapse (including local and regional recurrences, second-
ary primary and contralateral breast cancer), distantEarly N-, ER+ 
breast cancer 
patients
Uptake
3-100%
No Fa
Fai
8-2
No Uptake 
70-Gene 
strategy
70G is 
ordered
70G is not 
ordered
70G
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Figure 3 Scenario parameters as calculated in the model.metastasis, and death (Figure 3). It was assumed that
patients could only have one relapse, for which they
received the best available treatment with the same
costs, regardless which kind of adjuvant treatment the
patient originally received for the primary tumour. Theilure
lure
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lated time horizon of 20 years. The analyses were per-
formed from a health care perspective from the
Netherlands. Future costs and effects were discounted to
their present value by a rate of 4% and 1.5% per year re-
spectively, according to Dutch guidelines [31]. Costs
were expressed in 2005 Euros. We programmed the
model in Microsoft Excel (Microsoft, Redmond, WA).
In case of a technical failure, mainly due to insufficient
tissue quantity or -quality, the 70-gene signature could
not be performed and no result could be delivered to
the physician and patient. In some of these cases pre-
paratory costs were already made. It was assumed that
in these cases 10% of the total costs of the 70-geneTrue high
False low
False high
True low
High risk
Low risk
High r
Low r
High risk
Low risk High r
Low r
Risk 
profiles:
Treatment 
according to:
Surviv
accordin
Prognosis 
Disease
Deat
Local-regional 
or contralateral
relapse
Scenarios
Figure 4 Model structure.signature were made and the final treatment advice was
according to the clinical guideline (AO). In case of non-
compliance with a discordant test result, low risk signa-
ture and high risk AO or vice versa, the 70-gene signa-
ture result was available, but not used in the adjuvant
treatment decision. It was assumed that patients would
thus be treated according to the Adjuvant! Online result.
The uptake parameter reflected the proportion of the
target population (patients who actually did receive the
70-gene signature divided by all patients who are in
principle eligible for the signature (target population), ei-
ther 50% in 2010, in case of the “financial access” sce-
nario, and 92% in 2020, in case of the “progressive
uptake” scenario (Figure 4).Undertreatment
Overtreatment
Best available treatment
isk
isk
isk
isk
Best available treatment
al 
g to:
profiles
 free
h
Distant 
metastasis
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To reflect the dynamics in the diffusion, values of the
parameters were changed over time. Cost-effectiveness
was assessed for three points in time: 2005 (early adop-
tion, data available), 2010 (early majority phase, data
based on scenarios), 2020 (late majority, data based on
scenarios). All scenarios starting in 2005 were based on
data from the RASTER study [12], as well as the uncer-
tainty, which was assumed to stay constant over time.
The initial value of the technical failure parameter was
27%, as this occurred in the total available samples in
the RASTER-study. Based on the workshop results, we
assumed that the 27% failure rate would be reduced to
20% in 2010 and to 14% in 2020. Non-compliance was
modelled in case of a clinical high/genomic low risk
(15% in the RASTER-study) and in case of a clinical
low/genomic high risk (20%); thus in total 35% non-
compliance. Based on the scenarios, the total non-
compliance was likely to reduce to 26% in 2010 and to
8% in 2020, assuming a positive result of the MINDACT-
trial. The “uptake” parameter was calculated with the
numbers of patients who annually received a 70-gene sig-
nature divided by the incidence of the targeted group in
the Netherlands. We used the numbers of signatures per-
formed in the RASTER-study (n= 427) to feed the data of
2005 [12]. This specific parameter could be negatively
influenced by the “financial access” scenario, where the
uptake of the 70-gene signature is delayed by insurance
companies who do not reimburse the signature; or a
competitor test could enter the market with serious
effects on the likely sales, which we modelled with an up-
take probability of up to 50% in 2010. The uptake param-
eter could subsequently be positively influenced by the
“progressive uptake” scenario, where the 70-gene signa-
ture would be adopted optimally in Europe and embed-
ded in guidelines in up to 92% of cases in 2020.
Model analysis
The three “drivers of diffusion” parameters; failure,
non-compliance and uptake were separately integrated
in the Markov model, by changing only one specific
parameter and leaving the others fixed. In addition,
the parameters were combined per year; a 2010 sce-
nario (combination of the failure, non-compliance and
adoption scenarios in 2010) and a 2020 scenario (com-
bination of the failure, non-compliance and adoption
scenarios in 2020). For each scenario, the incremental
costs, effects and incremental cost-effectiveness ratio
(ICER) of the 70-gene signature versus the Adjuvant!
Online were calculated for 2005, 2010 and 2020. Incre-
mental effects and incremental costs were obtained by
subtracting the effects or costs of the Adjuvant! Online
strategy from the 70-gene signature strategy. The ICER
was calculated by dividing the difference in expectedcosts (ΔC) by the difference in expected effects (ΔE)
compared to a certain threshold value (λ) [32].
iNMB ¼ ΔE  λ ΔC
An ICER lower than the threshold implies that the 70-
gene signature is cost-effective compared to the AO, and
an ICER higher than the threshold implies that the 70-
gene signature is not cost-effective. The threshold
reflects the maximum willingness to pay of the society,
whether a strategy is deemed efficient depends on how
much society is willing to pay for a gain in effect, which
is referred to as the ceiling ratio [32]. As a threshold for a
positive decision on coverage, we used €30,000 per
QALY, which reflects the £20,000-30,000 per QALY ap-
plied by the National Institute for Health and Clinical Ex-
cellence (NICE) [33]. Parameter values were drawn at
random from the assigned distributions, using Monte
Carlo simulation with 1000 iterations. Uncertainty in the
input parameters was handled probabilistically, by
assigning distributions to parameters. To show decision
uncertainty, cost-effectiveness acceptability curves (CEACs)
frontiers are presented [34].
Results
Mean results
For the start in 2005, the effects and costs for the 70-
gene compared to the Adjuvant! Online strategy were al-
most equal; the incremental (difference in) QALYs were
0.0010 and the incremental costs amounted to €1,940
(Table 3). Over time, improvement was shown per separ-
ate scenario. The technical failure scenario resulted in
incremental effects of 0.0011 (2010) and 0.0013 (2020),
and incremental costs of €2,094 in 2010; and €2,385 in
2020. The observed higher costs for the 70-gene, were
due to more successful tests. The reduction of non-
compliance showed incremental effects of 0.0011 (2010)
and 0.0013 (2020), and incremental costs of €1,939 in
2010 and €1,940 in 2020. The uptake scenario resulted
in incremental effects of 0.0592 in 2010 and 0.1089 in
2020, and incremental costs of €1,547 in 2010, and
€1,211 in 2020.
Assuming a maximum willingness to pay of €30,000/
QALY, in 2005 the 70-gene signature was not yet cost-
effective compared to the current clinical guideline, with
an ICER of €1,9 million/quality-adjusted-life-year
(QALY). The ICER for the 70-gene signature improved
over time with a range of €1,9 million to €26,145 in
2010 and €1,9 million to €11,123/QALY in 2020 depend-
ing on the separate scenario used (Figure 5). The com-
bined scenarios of 2005, 2010 and 2020 showed that the
probability of cost-effectiveness of the 70-gene signature
for a maximum willingness to pay of €30,000/QALY is
56% in 2010, and will be 73% in 2020. In general, the
Table 3 Mean results, incremental effects, costs, cost-effectiveness ratio and Incremental Cost-Effectiveness Ratio
(ICER)
Model scenario time Mean value parameter Δeffects* Δcosts* ICER
failure NC uptake
Start 2005 0.27 0.35 0.03 0.0010 € 1,940 € 1,9 mill
Separate scenarios
Failure 2010 0.20 Idem Idem 0.0011 € 2,094 € 1,9 mill
2020 0.08 Idem Idem 0.0013 € 2,385 € 1,9 mill
Non-compliance 2010 Idem 0.26 Idem 0.0011 € 1,939 € 1,7 mill
2020 Idem 0.08 Idem 0.0013 € 1,940 € 1,5 mill
Uptake 2010 Idem Idem 0.50 0.0592 € 1,547 € 26,145
2020 Idem Idem 0.92 0.1089 € 1,211 € 11,123
Combined scenarios
2005 0.27 0.35 0.03 0.0010 € 1,940 € 1,9 mill
2010 0.20 0.26 0.50 0.0728 € 1,630 € 22,388
2020 0.08 0.08 0.92 0.1492 € 1,171 € 7,853
Δeffects: Incremental effects of 70-gene signature compared to the Adjuvant Online, Δcosts: Incremental costs of 70-gene signature compared to the Adjuvant
Online, ICER: Incremental cost-effectiveness ratio, NC: non compliance.
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effectiveness, followed by technical failures and non-
compliance.
Discussion
In the case of the 70-gene signature, the results of the
scenarios incorporated in the dynamic CEA showed a
wide range of possible ICERs over time. The effect of
uptake, failure and non-compliance give additional in-
formation on the speed with cost effectiveness might
be reached and thus provide a more realistic picture
for policy makers. In our view it might more often be
the case that real world variations are not accounted
for in cost-effectiveness analyses, as these often rely on
information from randomized controlled trials [35].0.00
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Figure 5 Cost-Effectiveness Acceptability Frontiers for the
combined “drivers for diffusion” scenarios.Besides for policy makers, this information can also be
valuable to guide implementation efforts and/or prod-
uct improvements.
This article shows that, in the absence of sufficient
data, scenarios can help to anticipate the future diffusion
patterns and use of technology by providing insight into
future developments. When integrated in a decision
model, these scenarios can also improve the ability to
make an informed policy decision. An advantage is that
scenario-discussion and -analysis reveals factors that can
be anticipated and may warrant intervention in the im-
plementation process, in order to stimulate “appropriate
use” and optimal cost-effectiveness at a population level.
In the case of the 70-gene signature, the influence of
the uptake scenario seemed to generate the highest im-
pact on the cost-effectiveness results. As the uptake of
the 70-gene signature increases, the net benefit will obvi-
ously increase and the 70-gene becomes cost-effective.
Informing doctors and patients and generating add-
itional evidence, for instance through “coverage with evi-
dence development” program, are possible means to
enhance uptake. When comparing the improved compli-
ance results with the reduction of failure results, failure
seemed to generate larger impact on cost-effectiveness,
mainly due to remaining costs for tests which failed
throughout the process. Compliance improvement was
observed actually in the pilot study of the MINDACT
with a total of 5 % non-compliance in the discordant
cases [27]. This was, however, measured in a trial design,
which may not be representative for use of the 70-gene
signature. Hesitant adopters will have the confidence
after prospective data is been released and ease of use
could be established by using the 70-gene signature in
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software as a hazard rate.
There are some remaining issues with regard to the
scenario method used. First, to keep the analysis stable,
we modelled the uncertainty constant over time. It is
true expecting that the uncertainty will decrease in the
future, but for the ease of comprehension, we left this
stable. We expect uncertainty will decrease over time,
for example when the results of the MINDACT trial will
become available. This is likely to make the results of
our analysis more favourable for the 70-gene signature.
By using value of information analysis (VOI) one can
characterise, and possibly deal, with uncertainty. We are
currently exploring these approaches [36,37]. Second,
the uptake scenario turned out to be most influential,
however, we could only use the numbers of the studies
conducted in 2005 and 2010, in real there could be a lot
more signatures used, and thereby effect the cost-
effectiveness of the 70-gene in a positive way. Further-
more, the reimbursement decision in this case is based
on knowledge and ideas regarding the accuracy of the
70-gene signature. This will indeed either accelerate or
slow down the uptake of the signature. In the scenarios,
we took into account a (delayed) uptake of 50% in 2010,
which is in fact the threshold for cost-effectiveness of
the 70-gene signature. Thus in case the uptake will stay
below the 50%, the 70-gene signature will not be consid-
ered cost-effective. Thirdly, in the scenario workshop,
most of the participants were already (short or long)
working with the 70-gene signature in clinical practice.
In our opinion, the experts who participated in the
workshop had a clear view of the potential barriers and
facilitators, because of their large experience and be-
cause they originated from different EU countries. How-
ever, more participants in the late majority or laggard
phases could possibly have changed the scenario likeli-
hoods. As a result, the scenarios might be more of a de-
celerating character, which would lead to higher costs
and less effect for the 70-gene signature. In addition, al-
ternative methods are available to elicit likelihoods of
different scenarios, such as a Delphi-like approach. Fi-
nally, it is possible that costs of drugs used in adjuvant
chemotherapy regimens may be underestimated because
the costs of Taxanes, used in adjuvant chemotherapy
regimen, are expected to increase in the coming years
[38].
The discussed method made it possible to integrate
qualitative scenarios into quantitative parameters and
derive scores from experts in order to obtain an impres-
sion on the most likely future developments. A next
phase could be to derive more quantitative scenarios, by
preparing the choices for the experts in a more quantita-
tive way, as has been described by some authors [39],
and by evaluating the different options against eachother. Another point of further research could be the
exact timing of performing a CTA using scenarios and
(retrospective) confirmation in other studies that dy-
namic CTA is possible.
With respect to the 70-gene signature, there is likely
to be more than one “truth” regarding cost-effectiveness,
especially in early stages of development. If we consider
expected costs and outcomes, we cannot be certain
about future developments. Technology Assessments in
uncertain diffusion phases may be occurring more often;
especially early stage cancer where researchers have to
wait up to 10–20 years for relevant outcome data.
Current advances in understanding cancer biology have
provided leads to develop new, effective targeted therap-
ies. However, progress is slowed by suboptimal/outdated
clinical trial design paradigms and by regulatory com-
plexity and rigidity. Ongoing studies like the Investiga-
tion of Serial studies to Predict Your Therapeutic
Response with Imaging And MoLecular analysis (the
ISPY-trial) are recent examples that using a new end-
point in the analyses (pathological complete response
(PCR)) can be considered to evaluate study results at an
earlier stage [40].
It is important to support those studies with a CTA in
order to monitor developments and anticipate them at
an early stage. Structured scenario drafting can be used
as a tool in this process, and seems especially suited to
integrate in decision-analytical models. This ultimately
provides the decision maker, opinion leader and/or
manufacturer with early, more detailed information of
possible developments and of a likely range of cost-
effectiveness results of a clinical technology, and the
aspects that can be relevant, to improve the product or
guide further diffusion.
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